0:49
GCLLSG 2016 | Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow
1:08
GCLLSG 2016 | Can concepts from CLL be applied to other liquid and solid tumors?
Paolo Ghia
1:00
GCLLSG 2016 | Why is personalized medicine important for CLL?
Petra Langerbeins
1:08
GCLLSG 2016 | The impact of genetic testing on treatment selection in CLL
Anna Schuh
1:38
GCLLSG 2016 | What are the economics of treating CLL?
John Gribben
1:14
GCLLSG 2016 | Prognostic markers for CLL – how do they help determine who gets which treatment?
Petra Langerbeins
2:08
GCLLSG 2016 | How does an understanding of the microenvironment aid research in CLL?
Paolo Ghia
1:02
GCLLSG 2016 | How to explain the ‘watch-and-wait’ period to a CLL patient?
Petra Langerbeins
1:15
GCLLSG 2016 | The role of transplant in CLL and Richter’s transformation today
Stephan Stilgenbauer
1:58
GCLLSG 2016 | Whole genome sequencing in CLL: challenges and benefits
Anna Schuh
2:32
GCLLSG 2016 | The importance of collaboration across fields and institutions
Dan Landau
2:23
GCLLSG 2016 | Key considerations for mutation detection in CLL
Anna Schuh
2:10
GCLLSG 2016 | Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Petra Langerbeins
2:02
GCLLSG 2016 | Current research at Weill Cornell and the New York Genome Center
Dan Landau
1:07
GCLLSG 2016 | Where are we with precision medicine for CLL?
John Gribben
2:09
GCLLSG 2016 | Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals